Apexian Pharmaceuticals Appoints CEO
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowApexian Pharmaceuticals Inc., previously known as ApeX Therapeutics, has appointed Steve Carchedi president and chief executive officer. He succeeds David Broecker, who is now CEO of the Indiana Biosciences Research Institute. Carchedi will also become a member of the company’s board of directors. Apexian recently announced acceptance by the U.S. Food and Drug Administration of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat cancer. Prior to joining Apexian, he was CEO of Cornerstone Pharmaceuticals. Carchedi has more than 30 years of experience building and developing specialty oncology companies. He previously served as senior vice president and president of commercial operations at Covidien and was instrumental in leading the successful spin-out of Mallinckrodt, now a $7.5 billion biopharmaceutical company. Earlier in his career, Carchedi led commercial development for several oncology products and programs at global pharmaceutical companies like Bristol Myers Squibb, Eli Lilly and Co. and Johnson and Johnson. He also serves on the board of directors for Sunesis Pharmaceuticals and Bionumerick Pharmaceuticals. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.